Enoxacin Interactions

Quinolone antimicrobial that inhibits CYP1A2; should be avoided due to significant increase in duloxetine concentrations.

Source: NLP:duloxetine

Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment.

Source: NLP:pirfenidone

Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.

Source: NLP:clozapine

Quinolone antimicrobial and potent CYP1A2 inhibitor that should be avoided due to potential significant increase in duloxetine concentrations.

Source: NLP:duloxetine hydrochloride

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Source: NLP:warfarin

CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

Source: NLP:warfarin sodium

Quinolone antimicrobial that inhibits CYP1A2 and may increase duloxetine concentrations.

Source: NLP:duloxetine d/r

CYP1A2 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.

Source: NLP:propranolol hydrochloride

CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Source: NLP:riluzole

CYP3A4 and CYP1A2 inhibitor that increases roflumilast systemic exposure and may result in increased adverse reactions.

Source: NLP:roflumilast